We came across a bullish thesis on Achieve Life Sciences, Inc. (ACHV) on Substack by Rogue Funds. In this article, we will summarize the bulls’ thesis on ACHV. Achieve Life Sciences, Inc. (ACHV)'s share was trading at $2.67 as of March 19th.
[caption id="attachment_572682" align="aligncenter" width="750"]Achieve Life Sciences presents a compelling investment opportunity with an exceptional risk-reward profile, particularly following its recent milestone update. The company's lead drug, Cytisinicline, is a nicotine cessation treatment...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.